沙利度胺联合肝动脉化疗栓塞治疗中晚期肝癌临床研究(精选).docVIP

沙利度胺联合肝动脉化疗栓塞治疗中晚期肝癌临床研究 尚 岩，陈 明 聪，江 慧 斌，徐 学 明，刘 树 勋 尚岩，1989年毕业于江苏徐州医学院医疗系，副主任医师，主要从事肿瘤化放疗和介入研究 通讯作者：尚岩 浙江省温岭市新河镇渡南头开发区 第二人民医院肿瘤内科 317502 E-mail：doctorsyzhj@ 固定电话：1座机电话号码18 摘 要 目的：探讨沙利度胺（TLD）联合肝动脉化疗栓塞 TACE 治疗中晚期原发性肝癌的临床疗效及不良反应。 方法：120例患者随机分为观察组和对照组各60例，观察组在TACE基础上加口服TLD，对照组不用TLD。 结果：近期疗效显示观察组肿瘤完全缓解（CR）8例，部分缓解（PR）45例，无变化（NC）4例，进展（PD）3例，总有效率为88.3%（p 0.05）。两组未见严重不良反应发生。随访3年，观察组1、2、3年生存率分别为73.3％、56.7％、36.7％；对照组为46.7％、30.0%、13.3％（p 0.05）。 结论：应用TLD联合TACE 治疗中晚期原发性肝癌疗效明显，不良反应轻，具有一定的临床应用价值。 关键词: 原发性肝癌；沙利度胺；肝动脉化疗栓塞 中图分类号： 文献标识码： 文章编号： The clinical study of transcatheter arterial chemoembolization combined with thalidomide on advanced hepatic carcinoma SHANG Yan, CHEN Ming-Cong, JIANG Hui-Bin, XU Xue-ming, LIU SHu-Xun, CHEN De-Lian Taizhou Cancer Hospital of Zhejiang Province, Wenling 317502, Zhejiang, China. ABSTRACT: AIM To observe the effect of transcatheter arterial chemoembolization combined with thalidomide（TLD）on advanced hepatic carcinoma. METHODS 120 advanced hepatic carcinoma patients were assigned to 2 groups. TLD group were treated by transcatheter arterial chemoembolization combined with TLD, and control group were only treated by TACE. The main outcome measure was the response rate and toxin response；secondary outcomes was overall survival rate. RESULTS The overall response rate was88.3percent in the TLD group and 63.3 percent in the control group（p 0.05）. There was not severely side-effect in the both groups. The overall 1, 2, 3-year survival rates were 73.3％,56.7％ and36.7％ in the TLD group, and 46.7％, 30.0% and 13.3％ in the control group. There were significant differences of the 2- and 3-year survival rate between the TLD group and the control group（p 0.05）. CONCLUSIONS Combined thalidomide with TACE is more effective than transcatheter arterial chemoembolization combined alone for the advanced hepatocellular carcinoma. Its adverse effects are tolerable，so it has certain value for clinical application． KEY WORDS hepatocellular carcinoma, thalidomide, tr